

Enzyme Immunoassay for the determination of Canine Distemper Virus antibody in Cat serum.

Catalog number: ARG82912

Package: 96 wells

For research use only. Not for use in diagnostic procedures.

# **TABLE OF CONTENTS**

SECTION	Page
INTRODUCTION	3
PRINCIPLE OF THE ASSAY	3
MATERIALS PROVIDED & STORAGE INFORMATION	4
MATERIALS REQUIRED BUT NOT PROVIDED	5
TECHNICAL HINTS AND PRECAUTIONS	5
SAMPLE COLLECTION & STORAGE INFORMATION	6
REAGENT PREPARATION	6
ASSAY PROCEDURE	7
CALCULATION OF RESULTS	8
OUALITY ASSURANCE	10

#### **MANUFACTURED BY:**

Arigo Biolaboratories Corporation

Address: 9F.-7, No. 12, Taiyuan 2nd St., Zhubei City,

Hsinchu County 302082, Taiwan

Phone: +886 (3) 622 1320

Fax: +886 (3) 553 0266

Email: info@arigobio.com

#### INTRODUCTION

In canines, CDV affects several body systems, including the gastrointestinal and respiratory tracts, the spinal cord, and the brain. Common symptoms include high fever, eye inflammation and eye/nose discharge, labored breathing and coughing, vomiting and diarrhea, loss of appetite and lethargy, and hardening of the nose and footpads. The viral infection can be accompanied by secondary bacterial infections and can eventually present serious neurological symptoms. Canine distemper is caused by a single-stranded RNA virus of the family Paramyxoviridae (the same family of viruses that causes measles, mumps, and bronchiolitis in humans). The disease is highly contagious via inhalation. Morbidity and mortality may vary greatly among animal species, with up to 100% mortality in unvaccinated populations of ferrets. In domestic dogs, while the acute generalized form of distemper has a high mortality rate, disease duration and severity depend mainly on the animal's age, immune status, and the virulence of the infecting strain of the virus. Despite extensive vaccination in many regions, it remains a major disease in dogs and was the leading cause of infectious disease death in dogs prior to a vaccine becoming available.

#### PRINCIPLE OF THE ASSAY

This assay employs the qualitative enzyme immunoassay technique. A specific canine distemper virus antigen has been pre-coated onto a microtiter plate. Standards or samples are pipetted into the wells and any canine distemper virus antibody present is bound by the immobilized antibody. After washing away any unbound substances, an HRP-conjugated antibody is added to each well and incubate. Following the washing of any unbound antibody-enzyme

reagent, a substrate solution (TMB) is added to the wells and color develops in proportion to the amount of antigen-antibody binding in the initial step. The color development is stopped by the addition of acid and the intensity of the color is measured at a wavelength of 450nm ±2nm.

## **MATERIALS PROVIDED & STORAGE INFORMATION**

Store the unopened kit at 2-8 °C. Use the kit before expiration date.

Component	Quantity	Storage information	
Antigen-coated microplate	8 X 12 strips	4°C. Unused strips should be sealed tightly in the air-tight pouch.	
Control A (Negative Control)	2ml (Ready-to-use)	4°C	
Control B (Cut-off Standard)	3ml (Ready-to-use)	4°C	
Control C (Positive Control)	2ml (Ready-to-use)	4°C	
HRP-Streptavidin solution	20 ml (Ready-to-use)	4°C	
Sample Diluent Buffer	100 ml (Ready-to-use)	4°C	
20X Wash Buffer	50 ml	4°C	
TMB Substrate	15 ml (Ready-to-use)	4°C (Protect from light)	
STOP Solution	15 ml (Ready-to-use)	4°C	
Plate sealer	1 e.a.	Room temperature	

## MATERIALS REQUIRED BUT NOT PROVIDED

- Microplate reader capable of measuring absorbance at 450nm (Optional:
   620 nm as reference wavelength)
- Pipettes and pipette tips
- Deionized or distilled water
- 37°C oven or incubator
- Automated microplate washer (optional)

#### TECHNICAL HINTS AND PRECAUTIONS

- Wear protective gloves, clothing, eye, and face protection especially while handling blood or body fluid samples.
- Store the kit at 4°C at all times and do not use after the expiry date.
- It is very important to bring all reagents and samples to room temperature (20-25°C) and mix them before starting the test run.
- Unused strips should be resealed in the aluminium foil along with the desiccant supplied and stored at 2-8 °C.
- If crystals are observed in the 20X Wash buffer, warm to RT or 37°C until the crystals are completely dissolved. Mix well before dilution.
- The TMB Color developing agent should be colorless (or could have a slight blue tinge) and transparent before using.
- Ensure complete reconstitution and dilution of reagents prior to use.
- All reagents should be mixed by gentle inversion or swirling prior to use. Do not induce foaming.
- Before using the kit, spin tubes and bring down all components to the bottom of tubes.
- All materials should be equilibrated to room temperature (RT; 20-25°C)
   before use.

- It is highly recommended that the standards, samples and controls be assayed in duplicates.
- Perform all assay steps in the order given and without any delays.
- Change pipette tips between the addition of different reagent or samples.
- For further internal quality control each laboratory should additionally use known samples.

#### SAMPLE COLLECTION & STORAGE INFORMATION

The sample collection and storage conditions listed below are intended as general guidelines. Sample stability has not been evaluated.

<u>Serum</u>- Use a serum separator tube (SST) and allow samples to clot for 30 minutes before centrifugation for 15 minutes at 1000 x g. Collect serum and assay immediately or aliquot and store samples at -20 or -70°C. Avoid repeated freeze-thaw cycles.

#### REAGENT PREPARATION

- 1X Wash buffer: Dilute 20X Wash buffer into distilled water to yield 1X Wash buffer. (e.g. 10 ml of 20X Wash buffer +190 ml of distilled water).
   Mix thoroughly by Use a magnetic stirrer. The diluted 1X wash buffer is stable for 5 days at room temperature (20-25 °C).
- Patient sample: Dilute patient sample 1:101 with Sample Diluent buffer before assay, mix well. (e.g. 5 μl of serum + 500 μl of Sample Diluent buffer)

**Note**: The controls are ready-to-use and need not further dilution.

#### **ASSAY PROCEDURE**

All materials should be equilibrated to room temperature (RT, 20-25 °C) before use. Standards, samples and controls should be assayed in duplicates.

- 1. Remove excess microplate strips from the plate frame, return them to the foil pouch containing the desiccant pack, and reseal it.
- Add 100 μl of controls, diluted samples (1:101) into wells. Leave one well
  empty for the Substrate Blank. Cover the wells and incubate for 1h at 37°C.
- 3. Aspirate each well and wash, repeating the process 2 times for a total 3 washes (for automatic systems wash the wells for a total 5 washes). Wash by filling each well with 1× Wash Buffer (300 μl) using a squirt bottle, manifold dispenser, or autowasher. Avoid overflows from the reaction wells. Keep the wash buffer in the wells for > 5 sec before removal. Complete removal of liquid at each is essential to good performance. After the last wash, remove any remaining Wash Buffer by aspirating, decanting or blotting against clean paper towels.

**Note:** If performing the test on ELISA automatic systems we recommend increasing the washing steps from **three** up to **five** and the volume of Washing Buffer from  $300 \, \mu L$  to  $350 \, \mu L$  to avoid washing effects.

- Add 100 μl of HRP-conjugated antibody into each well (except for the Substrate Blank well). Cover wells and incubate for 30 minutes at RT. (Do not expose to direct sunlight)
- 5. Aspirate each well and wash as step 3.
- 6. Add **100 μl** of **TMB Substrate Reagent** to each well. Incubate for **15 minutes** at **room temperature** in dark. A blue color occurs due to an enzymatic reaction.
- 7. Add  $100 \mu l$  of Stop Solution to each well. The color of the solution should

change from blue to yellow.

Read the OD with a microplate reader at 450 nm (and reference filter 620 nm) immediately. It is recommended read the absorbance within 30 minutes after adding the stop solution.

## **CALCULATION OF RESULTS**

- Calculate the average absorbance values for each set of standards, controls and patient samples.
- 2. Adjust the ELISA Microtiterplate reader to zero using the Substrate Blank.
- 3. Bichromatic measurement using a reference wavelength of 620 nm is recommended.
- 4. In order for an assay to be considered valid, the following criteria must be met:

Substrate blank: Absorbance value < 0.100

Negative control: Absorbance value < 0.200 and < cut-off

<u>Cut-off control</u>: Absorbance value **0.150- 1.300** 

Positive control: Absorbance value > cut-off

If these criteria are not met, the test is not valid and must be repeated.

5. Calculation of Results

The Cut-off is the mean absorbance value of the Cut-off Control determinations.

Example: Absorbance value of Cut-off Control well 1 = 0.5

absorbance value Cut-off control well 2 = 0.52

Control mean absorbance = Cut-off = (0.5+0.52)/2 = 0.51

6. Results in Units [U] (Ex.: If sample mean absorbance =1.2)

Units [U] = [Sample (mean) absorbance value x 10] / Cut-off

Example:  $(1.2 \times 10) / 0.51 = 23.5 \text{ U (Units)}$ 

Note: Cut-off = (Cut-off X 10) / Cut-off = 10 U

### 7. Interpretation of results:

- The samples are considered positive if the absorbance value is higher than 10% over the cut-off.
- Samples with absorbance value of 10% above or below cut-off should be considered in the grey zone.

It is recommended to repeat test again 2-4 weeks later with fresh sample. If the results in the second test are again in the grey zone, the sample has to be considered negative.

- Samples are considered negative if the absorbance value is lower than 10% below the cut-off.

#### Summary:

	Unit	Note
Cut-off	6.5 U	-
Positive	> 7 U	Antibodies against the pathogen are present.
		There has been a contact with the antigen
		(pathogen resp. vaccine)
Equivocal	6 – 7 U	Antibodies against the pathogen could not be
		detected clearly.
		It is recommended to repeat the test with a fresh
		sample in 2 to 4 weeks. If the result is equivocal
		again the sample is judged as <b>negative</b> .
Negative	< 6 U	The sample contains no antibodies against the
		pathogen.
		A previous contact with the antigen (pathogen

resp. vaccine) is unlikely.

Diagnosis of an infectious disease should not be established on the basis of a single test result. A precise diagnosis should take into consideration clinical history, symptomatology as well as serological data.

In immunocompromised patients and newborns serological data only have restricted value.

#### **QUALITY ASSURANCE**

## Intra-assay and Inter-assay precision

The CV values of intra-assay precision is 5.87% and inter-assay precision is 6.43%.

## **Diagnostic Specificity**

The diagnostic specificity is defined as the probability of the assay of scoring negative in the absence of the specific analytic.

It is 9231% (95% confidence interval: 63.97% -99.81%).

## **Diagnostic Sensitivity**

The diagnostic sensitivity is defined as the probability of the assay of scoring positive in the presence of the specific analytic.

It is 88.89% (95% confidence interval: 83.78% - 99.92%)

# **Cross Reactivity**

Cross-reactions cannot be excluded.

#### Interferences

Interferences are not significant interference effect observed up to concentration of 10 mg/mL hemoglobin, 5 mg/mL triglycerides and 0.5 mg/mL bilirubin.